

**2021 Hospitalist – Clinical Performance Registry (H-CPR)  
Measure Specifications Manual**

Measure #	Measure Title
-----------	---------------

Hospitalist Measures

- [HCPR14](#)    [Venous Thromboembolism \(VTE\) Prophylaxis](#)
- [ECPR51](#)    [Discharge Prescription of Naloxone after Opioid Poisoning or Overdose](#)
- [HCPR23](#)    [Avoidance of Echocardiogram and Carotid Ultrasound for Syncope](#)
- [ECPR56](#)    [Opioid Withdrawal: Initiation of Medication-Assisted Treatment \(MAT\) and Referral to Outpatient Opioid Treatment](#)

SNF Measures

- [HCPR16](#)    [Physician's Orders for Life-Sustaining Treatment \(POLST\) Form](#)
- [HCPR17](#)    [Pressure Ulcers – Risk Assessment and Plan of Care](#)
- [HCPR18](#)    [Unintentional Weight Loss – Risk Assessment and Plan of Care](#)

Critical Care Measures

- [HCPR20](#)    [Clostridium Difficile – Risk Assessment and Plan of Care](#)
- [HCPR22](#)    [Critical Care Transfer of Care – Use of Verbal Checklist or Protocol](#)

## **H-CPR (Hospitalist – Clinical Performance Registry) Measure #14**

*Adopted from 2017 Specifications Manual for National Hospital Quality Measure VTE-1*

**Measure Title:** Venous Thromboembolism (VTE) Prophylaxis

**Inverse Measure:** No

**Measure Description:** Percentage of Adult Patients Who Had VTE Prophylaxis Ordered at the Time of Admission OR Have Documentation of Reason for No VTE Prophylaxis

**National Quality Strategy Domain:** Patient Safety

**Care Setting:** Inpatient/Hospital

**Telehealth?:** Yes

**Type of Measure:** Process, High Priority

**Meaningful Measure Area:** Preventable Healthcare Harm

**Current Clinical Guideline:** This measure is derived from National Hospital Quality Measure VTE-1

**Clinical Category:** VTE

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Numerator:** Patients who had VTE prophylaxis ordered at the time of admission OR have documentation of reason for no VTE prophylaxis orders

### Numerator Options

- Performance Met (either of below qualify):
  - Acceptable VTE Prophylaxis (Note: This is not meant to be an inclusive list of all available anticoagulants; rather it represents current information available at the time of publication):
    - Pharmacologic Prophylaxis: Low dose unfractionated heparin (LDUH), Low molecular weight heparin (LMWH), Warfarin/Coumadin, IV Factor Xa Inhibitor such as Arixtra/Fondaparinux, Oral Factor Xa Inhibitor such as Xarelto/Rivaroxaban (must document why oral factor Xa was used for VTE Prophylaxis [acceptable reasons are: Atrial fibrillation, Atrial flutter, Hip arthroplasty/replacement, Total knee arthroplasty/replacement, or history of treatment for VTE or current VTE treatment])
    - Mechanical Prophylaxis: Intermittent pneumatic compression devices (IPC), Graduated compression stockings (GCS), Venous foot pumps (VFP)
  - Acceptable Reason(s) For No VTE Prophylaxis:
    - There is explicit documentation indicating that the patient is at low risk for VTE (i.e. Patient at low risk for VTE, No VTE Prophylaxis needed) OR
    - There is explicit documentation of a contraindication to both mechanical prophylaxis AND documentation of a contraindication to pharmacological

prophylaxis.

- Performance Not Met: No VTE prophylaxis ordered at the time of admission AND no documentation of reason for no VTE prophylaxis order

**Numerator Exclusions:** None

**Denominator:**

- Inpatients  $\geq 18$  years of age evaluated by the Eligible Professional (E/M Codes 99221-99223, 99231-99233, 99238-99239, 99291-99292 AND Place of Service Indicator: 21) PLUS
- LOS  $\geq 2$  days and  $\leq 120$  days
- Patients with Comfort Measures Only documented
- Patients enrolled in clinical trials are excluded

**Denominator Exclusions:** None

**Risk Adjustment:** No

**Rationale:**

(Adopted from 2017 Specifications Manual for National Hospital Quality Measure VTE-1) Hospitalized patients at high-risk for VTE may develop an asymptomatic deep vein thrombosis (DVT), and die from pulmonary embolism (PE) even before the diagnosis is suspected. The majority of fatal events occur as sudden or abrupt death, underscoring the importance of prevention as the most critical action step for reducing death from PE (Geerts, 2008).

The estimated annual incidence of deep-vein thrombosis (DVT) and pulmonary embolism (PE), known collectively as venous thromboembolism (VTE), is approximately 900,000 (Geerts, 2008). Approximately two-thirds of cases of DVT or PE are associated with recent hospitalization. This is consistent with the 2001 report by The Agency for Healthcare Research and Quality (AHRQ). AHRQ indicates that "the appropriate application of effective preventive measures in hospitals has major potential for improving patient safety by reducing the incidence of venous thromboembolism" (Shojania, 2001).

Despite its proven effectiveness, rates of appropriate thromboprophylaxis remain low in both medical and surgical patients. A recent analysis from the ENDORSE survey, which evaluated prophylaxis rates in 17,084 major surgery patients, found that more than one third of patients at risk for VTE (38%) did not receive prophylaxis and that rates varied by surgery type (Cohen, et al., 2008).

In a review of evidence-based patient safety practices, the Agency for Healthcare Research and Quality defined thromboprophylaxis against VTE as the "number one patient safety practice" for hospitalized patients (Shojania, 2001). Updated "safe practices" published by the National Quality Forum (NQF) recommend routine evaluation of hospitalized patients for risk of VTE and use of appropriate prophylaxis (National Quality Forum. National Voluntary Consensus Standards for Prevention and Care of Venous Thromboembolism, 2006).

As noted by the ACCP, a vast number of randomized clinical trials provide irrefutable evidence that thromboprophylaxis reduces VTE events, and there are studies that have also shown that fatal PE is prevented by thromboprophylaxis (Geerts, et al. 2008).

**Selected References:** (Adopted from 2017 Specifications Manual for National Hospital Quality Measure VTE-1)

- Amin A, Spyropoulos AC, Dobesh P, et al. Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). *J Thromb Thrombolysis*. 2010; 29:326-339.
- Caprini JA, Arcelus JI. State of the art venous thromboembolism prophylaxis. *SCOPE on Phlebology & Lymphology* 1:2005, 228-240.
- Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. *Lancet*. 2008;371:387-394.
- Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism. The Eighth ACCP Conference on antithrombotic and thrombolytic therapy. *Chest*. 2008; 133:381S-453S.
- Gillies TE, Ruckley CV, Nixon SJ. Still missing the boat with fatal pulmonary embolism. *Br J Surg*. 1996 Oct;83(10):1394.
- Goldhaber SZ, Tapson VF; DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound confirmed deep vein thrombosis. *Am J Cardiol*. 2004; 93:259-262.
- Guyatt, G.H., Akl, E.A., Crowther, M., Gutterman, D., Schunemann, H. Antithrombotic Therapy and Prevention of Thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *CHEST* 2012; 141(2)(Sup):7S-47S.
- Heit JA, Cohen AT, Anderson FA Jr, et al., Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US, *Blood (ASH Annual Meeting Abstracts)*, 2005;106:Abstract 910.
- Heit JA, Silverstein MD, Mohr DN, Petterson TM, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. *Arch Intern Med* 2000; 160:809-15.
- Hyers TM. Management of venous thromboembolism. *Arch Intern Med*. 2003;163:759-768.
- Kakkar AK, Cohen AT, Tapson VF, et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENDORSE survey): findings in surgical patients. *Ann Surg*. 2010;251:330-338.
- Kirwan CC, Nath E, Byrne GJ, McCollum CN. Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey. *BMJ* 2003;327:597-8.
- Kucher N, Koo S, Quiroz R, Cooper JM, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. *New England Journal of Medicine*. 2005, 352(10), 969-1036.
- Michota FA. Venous thromboembolism prophylaxis in medical patients. *Curr Opin Cardiol*. 2004 Nov;19(6):570-4.
- National Quality Forum. National Voluntary Consensus Standards for Prevention and Care of Venous Thromboembolism: Policy, Preferred Practices, and Initial Performance Measures. A Consensus Report. Washington, DC. *NQF*; 2006.
- Schleyer AM, Schreuder AB, Jarman KM, et al. Adherence to guideline-directed venous thromboembolism prophylaxis among medical and surgical inpatients at 33 academic medical centers in the United States. *Am J Med Qual*. 2011; 26:174-80.
- Shojania KG, Duncan BW, McDonald DM, et al. (Eds.). (2001). Making healthcare safer; A critical analysis of patient safety practices (Evidence Report/Technology Assessment No. 43). Prepared by the University of California at San Francisco-Stanford Evidenced-

based Practice Center under Contract no. 290-97-0013 (AHRQ Publication NO.01-E058). Rockville, MD:Agency for Healthcare Research and Quality.

- Tapson VF, Hyers TM, Waldo AL, et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. *Arch Intern Med.* 2005;165:1458-1464.
- Tooher R, Middleton P, Pham C, Fitridge R, et al. A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. *Ann Surg* 2005; 241:397-415.
- Wittkowsky AK. Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice. *Am J Manag Care.* 2004;10:S297-S30

## **H-CPR (Hospitalist – Clinical Performance Registry) Measure #16**

*Referenced Society of Post-Acute and Long-Term Care Medicine's Policy D-14: Promotion of Physician's Orders for Life-Sustaining Treatment Paradigm and the Institute of Medicine of the National Academies: Key Recommendations on Addressing End of Life*

**Measure Title:** Physician's Orders for Life-Sustaining Treatment (POLST) Form

**Inverse Measure:** No

**Measure Description:** Percentage of Patients Aged 65 Years and Older with Physician's Orders for Life-Sustaining Treatment (POLST) Forms Completed

**National Quality Strategy Domain:** Communication and Care Coordination

**Care Setting:** Post-Acute Care

**Telehealth?:** Yes

**Type of Measure:** Process, High Priority

**Meaningful Measure Area:** End of Life Care According to Preferences

**Current Clinical Guideline:** AMDA (The Society of Post-Acute and Long-Term Care Medicine) and the Institute of Medicine (IOM) of the National Academies support and promote the Physician's Orders for Life-Sustaining Treatment Paradigm

**Clinical Category:** End of Life Care

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Numerator:** Patients with a completed Physician's Orders for Life-Sustaining Treatment (POLST) form

### Definitions:

- Physician's Orders for Life-Sustaining Treatment (POLST) form is defined as a legally recognized, transportable and actionable medical order – intended for seriously ill patients at high risk for mortality – that remains with the patient whether at home, in the hospital, or in a care facility; the form indicates patient-specified medical treatment preferences and is signed by the authorizing physician, physician assistant (PA), or nurse practitioner (NP)
- The following elements must be present and completed in the Physician's Orders for Life-Sustaining Treatment (POLST) form:
  - Legally recognized decision maker verification
  - Cardiopulmonary Resuscitation (CPR) preferences (e.g., attempt CPR, DNR)
  - Medical Intervention (e.g., full code, comfort measures, limited/selective treatments)
  - Signed by eligible healthcare provider (e.g., physician, PA, or NP)
- NOTE: The approved version and title of the Physician's Orders for Life-Sustaining

Treatment (POLST) form may differ slightly from state to state; variations in forms are acceptable as long as the elements listed above are present

#### Numerator Options

- Performance Met:
  - Existing Physician's Orders for Life-Sustaining Treatment (POLST) form was acknowledged and documented in the medical record OR
  - Physician's Orders for Life-Sustaining Treatment (POLST) form was completed or updated and documented in the medical record OR
  - Documented reason for not acknowledging, completing or updating Physician's Orders for Life-Sustaining Treatment (POLST) form (e.g., patient refuses, patient is unresponsive or does not have capacity to complete, legally recognized decision maker is not present)
- Performance Not Met: Physician's Orders for Life-Sustaining Treatment (POLST) form was not acknowledged, completed or updated, reason not specified

**Numerator Exclusions:** None

#### **Denominator:**

- Adult patients aged  $\geq 65$  years evaluated by the Eligible Professional (E/M Codes 99221-99223, 99231-99233, 99238-99239, 99291-99292, 99304-99310, 99315, 99316)

**Denominator Exclusions:** None

**Risk Adjustment:** No

#### **Rationale:**

For patients and their family caregivers, control over treatment decisions is a high priority with an illness diagnosed as serious and life-limiting. (Singer et al, 1999) The Physician Orders for Life-Sustaining Treatments (POLST) form is designed to supplement and build upon advanced care planning and advanced directives. Unlike advanced directives, which are often generalized and require intermediaries on the patient's behalf (Bomba et al, 2012), the POLST form allows patients to clearly communicate their wishes regarding medical treatment and ensure that those wishes are honored across the care continuum by codifying their advanced directives as portable medical orders. Clinicians are able to focus on treatments desired by patients and avoid treatments that are unwanted by patients. These legally recognized, HIPAA-compliant forms follow the patients wherever they go (e.g., home, skilled nursing facility, acute care facility), and are intended to be completed for patients who are seriously ill and unlikely to recover (Moss et al., 2008). The POLST form includes key preferences (e.g., DNR status) that can be missed during patient transfers between facilities. The use of the POLST form prevents unwanted hospitalizations, readmissions and invasive medical procedures for patients who are near death. (Lee et al, 2000) AMDA (The Society of Post-Acute and Long-Term Care Medicine) and the Institute of Medicine (IOM) of the National Academies support and promote the Physician's Orders for Life-Sustaining Treatment Paradigm.

In a recent study, POLST completion was 49% in CA nursing home residents, identifying potential opportunity for quality improvement (Jennings).

#### **References:**

- AMDA – The Society for Post-Acute and Long-Term Care Medicine. Policy D-14: PHYSICIAN ORDERS FOR LIFE-SUSTAINING TREATMENT (POLST). <http://www.paltc.org/amda-white-papers-and-resolution-position-statements/physician-orders-life-sustaining-treatment>. Accessed December 22 2016.
- Basanta WE. (2002). Advance Directives and Life-Sustaining Treatment: A Legal Primer. *Hematology/Oncology Clinics of North America*;16(6):1381-96.
- Bomba PA, Kemp M, Black JS. (2012). POLST: An improvement over traditional advance directives. *Cleveland Clinic Journal of Medicine*;79(7):457-64.
- Dunne PM, Tolle SW, Moss AH, Black JS. (2007). The POLST Paradigm: Respecting the Wishes of Patients and Families. *Annals of Long-Term Care*;15(9):33-40.
- Fromme EK, Zive D, Schmidt TA, Cook JNB, Tolle SW. Association Between Physician Orders for Life-Sustaining Treatment for Scope of Treatment and In-Hospital Death in Oregon. *Journal of the American Geriatrics Society*;62(7):1246-51.
- Hammes B, Rooney BL, Gundrum JD, Hickman SE, Hager N. (2012) The POLST Program: A Retrospective Review of the Demographics of Use and Outcomes in One Community Where Advance Directives Are Prevalent. *Journal of Palliative Medicine*;15(1):77-85.
- Hartle GA, Thimons G, Angelelli J. (2014). *Nursing Research and Practice*, vol. 2014, Article ID 761784, 7 pages. doi:10.1155/2014/761784
- Hickman SE, Nelson CA, Moss AH, Hammes BJ, Terwilliger A, Jackson A, Tolle SW. (2009) Use of the Physician Orders for Life-Sustaining Treatment (POLST) Paradigm Program in the Hospice Setting. *Journal of Palliative Medicine*;12(2):133–41.
- Hickman SE, Nelson CA, Moss AH, Tolle SW, Perrin NA, Hammes BJ. (2011) The Consistency Between Treatments Provided to Nursing Facility Residents and Orders on the Physician Orders for Life- Sustaining Treatment (POLST) Form. *Journal of the American Geriatrics Society*;59(11):2091-99.
- Institute of Medicine (IOM) of the National Academies – Committee on Approaching Death: Addressing Key End of Life Issues. (2014) Key findings and recommendations. *Dying in America: Improving quality and honoring individual preferences near the end of life*. The National Academies Press. <http://www.nationalacademies.org/hmd/~media/Files/Report%20Files/2014/EOL/Key%20Findings%20and%20Recommendations.pdf> Accessed: January 6 2017.
- Kim H, Ersek M, Bradway C, Hickman SE. (2015) Physician Orders for Life-Sustaining Treatment for Nursing Home Residents with Dementia. *Journal of the American Association of Nurse Practitioners*;27(11):606-14.
- Lee MA, Brummel-Smith K, Meyer, J, et al. (2000). Physician Orders for Life-Sustaining Treatment (POLST): Outcomes in a PACE Program. *Journal of the American Geriatrics Society*;48(10):1219-25.
- Moss AH, Ganjoo, J, Sharma S, Gansor J, Senft S, Weaner B, Dalton C, MacKay K, Pellegrino B, Anantharaman P, Schmidt R. (2008). Utility of the “Surprise” Question to Identify Dialysis Patients with High Mortality. *Clinical Journal of the American Society of Nephrology*;3(5):1379–84.
- Nisco M, Mittelberger J, Citko J. POLST: An Evidence-Based Tool for Advance Care Planning. <http://www.nphco.org>. Accessed: November 27 2016.
- Singer PA, Martin DK, Kelner M. (1999). Quality End of Life Care: Patients’ Perspective. *Journal of the American Medical Association*. 281: 163-68.
- Tolle SW, Tilden VP, Nelson CA, Dunn PM. (1998). A Prospective Study of the Efficacy of the Physician Order Form for Life-sustaining Treatment. *Journal of the American Geriatrics Society*;46(9):1097-102.



- Vandenbroucke A, Nelson S, Bomba P, Moss AH. (2013) POLST: Advance Care Planning for the Seriously Ill. <http://www.polst.org/>. Accessed: November 27 2016.
- Jennings, L.A., Zingmond, D., Louie, R. et al. J GEN INTERN MED (2016) 31: 1119. <https://doi.org/10.1007/s11606-016-3728-9>

## **H-CPR (Hospitalist – Clinical Performance Registry) Measure #17**

*Referenced National Pressure Ulcer Advisory Panel's 2014 Prevention and Treatment of Pressure Ulcers: Clinical Practice Guidelines*

**Measure Title:** Pressure Ulcers – Risk Assessment and Plan of Care

**Inverse Measure:** No

**Measure Description:** Percentage of Adult Post-acute Facility Patients That Had a Risk Assessment for Pressure Ulcers and a Plan of Care for Pressure Ulcer Prevention/Treatment Completed

**National Quality Strategy Domain:** Patient Safety

**Care Setting:** Post-Acute Care

**Telehealth?:** Yes

**Type of Measure:** Process, High Priority

**Meaningful Measure Area:** Preventable Healthcare Harm

**Current Clinical Guideline:** This measure aims to reduce the incidence of pressure ulcers which are included in the AHRQ PSI-90; it also supports the National Pressure Ulcer Advisory Panel's Prevention and Treatment of Pressure Ulcers Clinical Practice Guidelines

**Clinical Category:** Pressure Ulcers

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Numerator:** Adult Post-acute Facility Patients that Had a Risk Assessment for Pressure Ulcers and a Plan of Care for Pressure Ulcer Prevention OR Treatment Documented

### Definitions

- Pressure ulcer: Localized damage to the skin and/or underlying soft tissue usually over a bony prominence or related to a medical or other device. The injury can present as intact skin or an open ulcer and may be painful. The injury occurs as a result of intense and/or prolonged pressure or pressure in combination with shear.
- Risk assessment:
  - Nationally recognized scale (e.g., Braden Scale or Braden Q Scale)
  - Nutrition
  - Activity and Mobility Limitations
  - History of skin breakdown
  - Cognition
- Plan of care – Prevention:
  - Scheduled skin integrity assessments
  - Minimize friction and shear
  - Minimize pressure with off-loading

- Manage moisture
- Maintain adequate nutrition and hydration
- Plan of care – Treatment:
  - Scheduled wound description/staging
  - Etiology of pressure (e.g., dementia, diapering)
  - Body repositioning
  - Nutritional status
  - Bacterial colonization/infection
  - Wound management (e.g., wound dressings, barrier creams, medicated creams, antibiotics, gauze)

#### Numerator Options

- Performance Met: Patients who did have pressure ulcer risk assessment AND a plan of care for pressure ulcer prevention or treatment documented
- Performance Not Met: Patients who did not have pressure ulcer risk assessment AND a plan of care for pressure ulcer prevention or treatment documented

**Numerator Exclusions:** None

#### **Denominator:**

- Adult patients aged  $\geq 18$  years evaluated by the Eligible Professional in the Post-acute Facility (E/M Codes 99304-99310, 99315, 99316)

**Denominator Exclusions:** None

**Risk Adjustment:** No

#### **Rationale:**

Pressure ulcers have been associated with an extended length of hospitalization, sepsis and mortality. About 60,000 United States patients are estimated to die yearly from hospital-acquired pressure ulcers and their complications. (Sullivan, 2013) Pressure ulcers cause deep muscle and tissue damage that can require lengthy recovery times, depending on various risk factors, including age, blood pressure, body temperature, and protein intake. Pressure ulcers are also associated with fatal septic infections. (Redelings et al., 2005; Brem et al., 2010; Lyder, 2003) In addition, the risk of pressure ulcer development increases among older patients and among patients with cardiovascular and endocrine diseases. The total cost for treatment of pressure ulcers in the United States is estimated at \$11 billion per year (Ackroyd-Stolarz, 2011), with an approximate financial impact of \$18.8 million of Medicare program payments annually. (Kandilov et al., 2014) In post-acute care facilities, pressure ulcers can cost Medicare as much as \$15,000 in treatments (Kandilov et al., 2014) and can range between \$500 to \$40,000 per pressure ulcer treated. (Lyder, 2003)

The care provided by clinicians, which includes implementation of an effective risk assessment and a plan of care for prevention of pressure ulcers or active treatment for patients with developing pressure ulcers, is critical to improving patient outcomes (Siem et al, 2003) and saving costs through comprehensive prevention efforts (Tippett, 2009). The National Pressure Ulcer Advisory Panel's recommendations state that clinicians are responsible for the following: reviewing risk factors and identifying potential causes for development of pressure ulcers; implementing focused interventions to reduce, stabilize, and remove risk factors; and

implementing targeted pressure injury management protocols as needed (NPUAP Quality of Care Regulations).

### **Selected References:**

- Ackroyd-Stolarz S. Improving the prevention of pressure ulcers as a way to reduce health care expenditures. *CMAG*. 2014 Jul;186(10):E370-E371.
- Brem H, Maggi J, Nierman D, Rolnitzky L, Bell D, Rennert R, Golinko M, Yan A, Lyder C, Vladeck B. High cost of stage IV pressure ulcers. *Am J Surg*. 2010 Oct;200(4):473-77.
- Chen HL, Shen WQ, Liu P. A meta-analysis to evaluate the predictive validity of the Braden scale for pressure ulcer risk assessment in long-term care. *Ostomy Wound Manage*. 2016 Sep;62(9):20-8.
- Cuddigan J, Berlowitz DR, Ayello EA. Pressure ulcers in America: prevalence, incidence, and implications for the future. An executive summary of the National Pressure Ulcer Advisory Panel monograph. *Adv Skin Wound Care*. 2001 Jul-Aug;14(4):208-15.
- Institute for Clinical Systems Improvement (ICSI). Pressure ulcer prevention and treatment protocol. Health care protocol. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2012 Jan. 88 p. [112 references]
- Kandilov, AMG, Coomer NM, Dalton, K. The impact of hospital-acquired conditions on medicare program payments. *Medicare Medicaid Res Rev*. 2014 Oct;4(4):mmrr2014-004-04-a01.
- Lyder, CH. Pressure ulcer prevention and management. *JAMA*. 2003 Jan 8;289(2):223-6
- Minnesota Department of Health. Adverse health events in Minnesota: seventh annual public report. 2011 Jan.
- National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and treatment of pressure ulcers: quick reference guide.
- National Pressure Ulcer Advisory Panel. The NPUAP selected "Quality of Care Regulations" made easy. Accessed December 22 2016. <http://www.npuap.org/wp-content/uploads/2014/03/NPUAP-F-tag-final-March-2014.pdf>
- Niederhauser A, VanDeusen Lukas C, Parker V, Ayello EA, Zulkowski K, Berlowitz D. Comprehensive programs for preventing pressure ulcers: a review of the literature. *Adv. Skin Wound Care*. 2012 Jul.;25(4):167-88.
- Park-Lee, E. Caffrey, C. Pressure ulcers among nursing home residents: United States, 2004. *NCHS Data Brief*. 2009 Feb.
- Redelings, MD. Lee, NE. Sorvillo, F. Pressure ulcers: more lethal than we thought? *Adv. Skin Wound Care*. 2005 Sep; 18(7):367-72.
- Siem CA, Wipke-Tevis DD, Rantz MJ, Popejoy LL. Skin assessment and pressure ulcer care in hospital-based skilled nursing facilities. *Ostomy Wound Manage*. 2003 Jun; 49(6):42-4.
- Stechmiller JK, Cowan L, Whitney JD, Phillips L, Aslam R, Barbul A, Gottrup F, Gould L, Robson MC, Rodeheaver G, Thomas D, Stotts N. Guidelines for the prevention of pressure ulcers. *Wound Repair Regen*. 2008 Mar-Apr;16(2):151-68.  
Sullivan N. Preventing In-Facility Pressure Ulcers. In: *Making Health Care Safer II: An Updated Critical Analysis of the Evidence for Patient Safety Practices*. Rockville (MD):

Agency for Healthcare Research and Quality (US); 2013 Mar. (Evidence Reports/Technology Assessments, No. 211.) Chapter 21. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK133388/>

- Tippett, AW. Reducing the incidence of pressure ulcers in nursing home residents: A prospective 6-year evaluation. *Ostomy Wound Manage.* 2009 Nov; 55(11):52-8.
- White-Chu EE, Reddy M. Wound care in short-term rehabilitation facilities and long-term care: special needs for a special population. *Skinmed.* 2012 Mar-Apr; 10(2):75-81.
- Wound, Ostomy, and Continence Nurses Society. Prevalence and incidence: a toolkit for clinicians. Glenview (IL): WOCN; 2004.
- Sullivan N. Preventing In-Facility Pressure Ulcers. In: *Making Health Care Safer II: An Updated Critical Analysis of the Evidence for Patient Safety Practices.* Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Mar

## **H-CPR (Hospitalist – Clinical Performance Registry) Measure #18**

*Referenced NQF 0689: Percent of Residents Who Lose Too Much Weight*

**Measure Title:** Unintentional Weight Loss – Risk Assessment and Plan of Care

**Inverse Measure:** No

**Measure Description:** Percentage of Adult Post-acute Facility Patients that Had a Risk Assessment for Unintentional Weight Loss and a Plan of Care for Unintentional Weight Loss Documented by Provider

**National Quality Strategy Domain:** Patient Safety

**Care Setting:** Post-Acute Care

**Telehealth?:** Yes

**Type of Measure:** Process, High Priority

**Meaningful Measure Area:** Preventive Care

**Current Clinical Guideline:** This measure is derived from NQF 0689: Percent of Residents Who Lose Too Much Weight

**Clinical Category:** Weight Loss

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Numerator:** Adult Post-acute Facility Patients that Had a Risk Assessment for Unintentional Weight Loss, Reason for Weight Loss (If Applicable) and a Plan of Care for Unintentional Weight Loss Documented

### Definitions

- Weight loss episode: A loss of weight equal to or greater than 5% within a 30-day period or 10% within a 180-day period
  - Starting with the patient's weight closest to 30 days ago, the patient's current weight is equal to or less than 95%. Starting with the patient's weight closest to 180 days ago, the patient's current weight is equal to or less than 90%
- Risk Assessment:
  - Nationally recognized tool [e.g., Minimum Data Set (MDS) Swallowing/Nutritional Status, Mini Nutritional Assessment (MNA), Malnutrition Screening] Tool (MST)] which includes the following:
    - Weight
    - Height
    - Body Mass Index (BMI)
    - Recent Weight loss
    - Recent Intake (e.g. reduced intake, nutritional approach)
    - Swallowing Disorder

- Severity of Disease
- Plan Of Care:
  - Oral nutrition support (e.g., therapeutic diet, mechanically altered diet, condition specific diet, fortified foods, and/or supplements)
  - Parenteral feeding
  - Enteral feeding tube
  - Patient-centered and/or condition-specific considerations (e.g., prescription of orexigenic alternatives to anorectic drugs, hydration and edema status, increased nutritional needs for patients at high risk of pressure ulcers, patient preferences and availability of choices for foods and fluids, feeding assistance by staff to enhance the resident's self-feeding ability, social stimulation throughout meal or snack period)

#### Numerator Options

- Performance Met: Patients who did have a risk assessment for unintentional weight loss, reason for weight loss (if applicable) AND a plan of care for unintentional weight loss documented
- Performance Not Met: Patients who did not have a risk assessment for unintentional weight loss, reason for weight loss (if applicable) AND a plan of care for unintentional weight loss documented

**Numerator Exclusions:** None

#### **Denominator:**

- Adult patients aged  $\geq 18$  years evaluated by the Eligible Professional in the Post-acute Facility (E/M Codes 99304-99310, 99315, 99316)

**Denominator Exclusions:** None

**Risk Adjustment:** No

**Rationale:** Unintended and excessive weight loss is a significant problem among nursing home residents. CMS Nursing Home Compare reports that 7% of nursing home residents experience excessive weight loss nationally, and other studies report rates of up to 20% or 33% (Bell et al., 2016, Gaddey & Holder, 2014). Weight loss of 5% or more in one month or 10% or more over six months is considered unhealthy (Thomas et al., 2000), and studies have found an association between weight loss and increased morbidity and mortality (Sullivan et al., 2002; Stack et al., 2013; Keller et al., 2015).

Nutritional issues have been identified as a priority area for practice change and research in long-term care (Keller et al., 2015; Morley et al., 2014; Rolland et al., 2011). In long-term care, the primary cause of malnutrition is poor food and fluid intake (Keller et al., 2014, Bell et al., 2013). Nursing home residents often have chronic diseases and functional impairments that may impair proper nutrition and hydration (Morley, 2007; Sloane et al., 2008; Bourdel-Marchasson, 2010) and require medical interventions (Morley, 2007). Various chronic illnesses are associated with malnutrition, including cancer, diabetes, depression, and chronic obstructive pulmonary disease (COPD) (Huffman, 2002). Medications, oral health problems (such as missing teeth), dysphagia, and dementia can complicate nutrition and hydration. Medications may cause nausea, anxiety, constipation, and lack of appetite. Depression has been identified as the "most common reversible illness" associated with malnutrition (Sloane et

al., 2008). Dehydration is a major factor in weight loss in about 10% of nursing home residents (Kaldy et al., 2000; Feinsod et al., 2004; Smith, 2006). A review study demonstrated that weight loss is the most objective and reproducible marker of nutritious status for nursing home residents (Bell et al., 2013).

Elderly individuals with excessive and rapid weight loss are at higher risk for readmissions, extended stays (Stratton 2006), functional decline, hip fracture (Langlois et al., 2001; Ensrud et al., 2003) and mortality (Covinsky et al., 1999; Kiely & Flacker, 2000; Sullivan et al., 2002; Wedick et al., 2002; Keller & Ostbye, 2005; Amador et al., 2006; Stack et al., 2013). Detecting and preventing weight loss is central to ensure appropriate nutritional intake.

Care processes have been found to influence the nutritional intake and risk of weight loss for the elderly (Simmons et al., 2001; Altus, Engelman, & Matthews, 2002; Pelletier, 2004; Milne et al., 2009; Simmons et al., 2003). Nutrition and dining programs may potentially reduce the risk of weight loss for nursing home residents. For example, a Cochrane meta-analysis found that supplementation produces small but consistent weight gain in older people (Milne et al., 2009). Appropriate management of clinical conditions for people at higher risk for weight loss (e.g., those with depression) is also a potentially effective way to prevent unintended weight loss (Malone, 2005; Rigler et al., 2001).

Several national guidelines from organizations such as the American Dietetic Association, the Gerontological Society of America, the Council for Nutritional Strategies in Long-Term Care (Thomas 2000), the American Medical Directors Association, the National Institute for Health Care and Excellence (NICE 2006), the American Academy of Nutrition and Dietetics (White 2012), and the American Society of Parenteral and Enteral Nutrition (ASPEN) (Mueller 2011, White 2012), recommend nutritional risk assessments for unintentional weight loss and documented plans of care for inpatients, outpatients, skilled nursing and long-term care patients.

Several national risk assessment instruments have also been validated and endorsed by national organizations. The [Minimum Data Set \(MDS 3.0\) Nursing Home Comprehensive Item Set Chapter K: Swallowing/Nutrition Status](#) is required by the Centers for Medicare and Medicaid Services (CMS) for all skilled nursing facility prospective payment system patients to assess both swallowing and nutritional status as well as a care plan. [The Mini Nutritional Assessment \(MNA\)](#), both the full assessment and the short form (SF) classifies older people as well-nourished, at risk for malnutrition or malnourished. The [Alliance to Advance Patient Nutrition](#) has developed the [Malnutrition Screening Tool \(MST\)](#) and an entire toolkit of resources for physicians, nurses and patients to improve patient's nutritional status. Both risk assessment and care planning involves establishing a course of action with input from the clinician, nursing, dieticians, and the resident (as well as resident's family and/or guardian or other legally authorized representative) to improve their nutritional status.

### **Selected References:**

- Alliance to Advance Patient Nutrition. Malnutrition Screening Tool (MST). 2014. Accessed on December 2, 2016. Accessed at [http://static.abbottnutrition.com/cms-prod/malnutrition.com/img/Alliance\\_Malnutrition\\_Screening\\_Tool\\_2014\\_v1.pdf](http://static.abbottnutrition.com/cms-prod/malnutrition.com/img/Alliance_Malnutrition_Screening_Tool_2014_v1.pdf).
- Altus DE, Engelman KK, Mathews RM. Using family-style meals to increase participation and communication in persons with dementia. *J Gerontol Nurs.* 2002 Sep;28(9):47-53.
- Amador LF, Al Snih S, Markides KS, Goodwin JS. Weight change and mortality among older Mexican Americans. *Aging Clin Exp Res.* 2006 Jun;18(3):196-204.



- Bell CL, Tamura BK, Masaki KH, Amella EJ. Prevalence and measures of nutritional compromise among nursing home patients: weight loss, low body mass index, malnutrition, and feeding dependency, a systematic review of the literature. *J Am Med Dir Assoc.* 2013 Feb;14(2):94-100.
- Bell SP, Vasilevskis EE, Saraf AA, Jacobsen JM, Kripalani S, Mixon AS, Schnelle JF, Simmons SF. Geriatric syndromes in hospitalized older adults discharged to skilled nursing facilities. *Journal of the American Geriatrics Society.* 2016 Apr;64(4):715-22.
- Bourdel-Marchasson I. How to improve nutritional support in geriatric institutions. *J Am Med Dir Assoc.* 2010 Jan;11(1):13-20. [74 references]
- Cereda E, Pedrolli C. The geriatric nutritional risk index. *Current Opinion in Clinical Nutrition and Metabolic Care* 2009, 12:1–7
- Cereda E. Mini nutritional assessment. *Curr Opin Clin Nutr Metab Care* 2012, 15:29–41.
- Covinsky KE, Martin GE, Beyth RJ, Justice AC, Sehgal AR, Landefeld CS. The relationship between clinical assessments of nutritional status and adverse outcomes in older hospitalized medical patients. *J Am Geriatr Soc.* 1999 May;47(5):532-8.
- Ensrud KE, Ewing SK, Stone KL, Cauley JA, Bowman PJ, Cummings SR. Intentional and unintentional weight loss increase bone loss and hip fracture risk in older women. *J Am Geriatr Soc.* 2003 Dec;51(12):1740-7.
- Feinsod FM, Levenson SA, Rapp K, Rapp MP, Beechinor E, Liebmann L. Dehydration in frail, older residents in long-term care facilities. *J Am Med Dir Assoc.* 2004 Mar-Apr;5(2 Suppl):S35-41. [38 references]
- Gaddey HL, Holder K. Unintentional weight loss in older adults. *Am Fam Physician.* 2014 May 1;89(9):718-22.
- Huffman GB. Evaluating and treating unintentional weight loss in the elderly. *Am Fam Physician.* 2002 Feb 15;65(4):640-50. [43 references]
- Keller H, Beck AM, Namasivayam A, International-Dining in Nursing Home Experts (I-DINE) Consortium. Improving food and fluid intake for older adults living in long-term care: a research agenda. *J Am Med Dir Assoc.* 2015 Feb;16(2):93-100.
- Keller HH, Ostbye T. Body Mass Index (BMI), BMI change and mortality in community-dwelling seniors without dementia. *J Nutr Health Aging.* 2005 Sep-Oct;9(5):316-20.
- Kiely DK, Flacker JM. Resident characteristics associated with mortality in long-term care nursing homes: is there a gender difference. *J Am Med Dir Assoc.* 2000 Jan-Feb;1(1):8-13.
- Langlois JA, Mussolino ME, Visser M, Looker AC, Harris T, Madans J. Weight loss from maximum body weight among middle-aged and older white women and the risk of hip fracture: the NHANES I epidemiologic follow-up study. *Osteoporos Int.* 2001;12(9):763-8.
- Malone M. Medications associated with weight gain. *Ann Pharmacother.* 2005 Dec;39(12):2046-55.
- Milne AC, Potter J, Vivanti A, Avenell A. Protein and energy supplementation in elderly people at risk from malnutrition. *Cochrane Database Syst Rev.* 2009 Apr 15;(2):CD003288.
- Morley JE, Caplan G, Cesari M, Dong B, Flaherty JH, Grossberg GT, Holmerova I, Katz PR, Koopmans R, Little MO, Martin F, Orrell M, Ouslander J, Rantz M, Resnick B, Rolland Y, Tolson D, Woo J, Vellas B. International survey of nursing home research priorities. *J Am Med Dir Assoc.* 2014 May;15(5):309-12.
- Morley JE. Weight loss in the nursing home. *J Am Med Dir Assoc.* 2007 May;8(4):201-4.
- Mueller C, Compher C, Ellen DM, American Society for Parenteral and Enteral Nutrition (ASPEN) Board of Directors. [ASPEN clinical guidelines: Nutrition screening, assessment, and intervention in adults.](#) *J Parenter Enteral Nutr.* 2011 Jan;35(1):16-24.

- National Collaborating Centre for Acute Care, February 2006. Nutrition support in adults Oral nutrition support, enteral tube feeding and parenteral nutrition. <https://www.nice.org.uk/guidance/cg32/evidence/full-guideline-194889853>
- Centers for Medicare and Medicaid Services, Nursing Home Compare. Quality of resident care ratings. 2017
- Omran ML, Morley JE. Assessment of protein energy malnutrition in older persons, part I: history, examination, body composition, and screening tools. *Nutrition* 2000; 16:50–63.
- Omran ML, Morley JE. Assessment of protein energy malnutrition in older persons, part II: laboratory evaluation. *Nutrition* 2000; 16:131–140.
- Pelletier CA. What do certified nurse assistants actually know about dysphagia and feeding nursing home residents? *Am J Speech Lang Pathol.* 2004 May;13(2):99-113.
- Rigler SK, Webb MJ, Redford L, Brown EF, Zhou J, Wallace D. Weight outcomes among antidepressant users in nursing facilities. *J Am Geriatr Soc.* 2001 Jan;49(1):49-55.
- Rolland Y, Aquino JP, Andrieu S, Beard J, Benetos A, Berrut G, Coll-Planas L, Dartigues JF, Dong B, Forette F, Franco A, Franzoni S, Hornez T, Metais P, Ruault G, Stephan E, Swagerty D, Tolson D, Volicer L, Vellas B, Morley J. Identification of the main domains for quality of care and clinical research in nursing homes. *J Nutr Health Aging.* 2011 May;15(5):410-24.
- Simmons SF, Alessi C, Schnelle JF. An intervention to increase fluid intake in nursing home residents: prompting and preference compliance. *J Am Geriatr Soc.* 2001 Jul;49(7):926-33.
- Simmons SF, Garcia ET, Cadogan MP, Al-Samarrai NR, Levy-Storms LF, Osterweil D, Schnelle JF. The minimum data set weight-loss quality indicator: does it reflect differences in care processes related to weight loss? *J Am Geriatr Soc.* 2003 Oct;51(10):1410-8.
- Simmons SF, Osterweil D, Schnelle JF. Improving food intake in nursing home residents with feeding assistance: a staffing analysis. *J Gerontol A Biol Sci Med Sci.* 2001 Dec;56(12):M790-4.
- Simmons SF, Keeler E, Zhuo X, Hickey KA, Sato H, Schnelle JF. Prevention of Unintentional Weight Loss in Nursing Home Residents: A Controlled Trial of Feeding Assistance. *Journal of the American Geriatrics Society.* 2008;56(8):1466-1473. Sloane PD, Ivey J, Helton M, Barrick AL, Cerna A. Nutritional issues in long-term care. *J Am Med Dir Assoc.* 2008 Sep;9(7):476-85. [68 references]
- Smith PA. Nutrition, hydration, and dysphagia in long-term care: Differing opinions on the effects of aspiration. *J Am Med Dir Assoc.* 2006 Nov;7(9):545-9.
- Stack S, Chertow GM, Johansen KL, Si Y, Tamura MK. Pre-ESRD changes in body weight and survival in nursing home residents starting dialysis. *Clin J Am Soc Nephrol.* 2013 Oct;8(10):1734-40.
- Stratton RJ, King CL, Stroud MA. Malnutrition Universal Screening Tool predicts mortality and length of stay in hospital elderly. *Br J Nutr* 2006; 95: 325-330.
- Sullivan DH, Morley JE, Johnson LE, Barber A, Olson JS, Stevens MR, Yamashita BD, Reinhart SP, Trotter JP, Olave XE. The GAIN (Geriatric Anorexia Nutrition) registry: the impact of appetite and weight on mortality in a long-term care population. *J Nutr Health Aging.* 2002;6(4):275-81.
- Thomas DR, Ashmen W, Morley JE, Evans WJ. Nutritional management in long-term care: development of a clinical guideline. *Council for Nutritional Strategies in Long-Term Care. J Gerontol A Biol Sci Med Sci.* 2000 Dec;55(12):M725-M734.
- Wedick NM, Barrett-Connor E, Knoke JD, Wingard DL. The relationship between weight loss and all-cause mortality in older men and women with and without diabetes mellitus: the Rancho Bernardo study. *J Am Geriatr Soc.* 2002 Nov;50(11):1810-5.
- White et al. Consensus Statement: Academy of Nutrition and Dietetics and American

Society for Parenteral and Enteral Nutrition: Characteristics Recommended for the Identification and Documentation of Adult Malnutrition (Undernutrition). Journal of Parenteral and Enteral Nutrition 2012: Vol 36, Issue 3, pp. 275 – 283  
<http://journals.sagepub.com/doi/pdf/10.1177/0148607112440285>

## **H-CPR (Hospitalist – Clinical Performance Registry) Measure #20**

**Measure Title:** Clostridium Difficile – Risk Assessment and Plan of Care

**Inverse Measure:** No

**Measure Description:** Percentage of Adult Patients Who Had a Risk Assessment for C. difficile Infection and, If High-Risk, Had a Plan of Care for C. difficile Completed on the Day Of or Day After Hospital Admission

**National Quality Strategy Domain:** Patient Safety

**Care Setting:** Inpatient/Hospital

**Telehealth?:** Yes

**Type of Measure:** Process, High Priority

**Meaningful Measure Area:** Healthcare-associated Infections

**Current Clinical Guideline:** This preventive screening is supported by the CDC, IDSA, SHEA, AHA, and Joint Commission.

**Clinical Category:** C. Diff

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Numerator:** Patients that had a risk assessment for C. difficile infection and, if high-risk, a plan of care documented on the day of or day after hospital admission

### Definitions:

- Risk assessment (e.g., IDSA score, SHEA score, ZAR criteria):
  - Previous C. difficile infection
  - Recent antibiotic use (60-90 days prior to current admission)
  - Recent contact with healthcare facility (60-90 days prior to current admission)
  - Age  $\geq$  65
  - Recent use of proton pump inhibitor (PPI) or histamine receptor 2 antagonists (H2RA)
  - Diagnosis and procedure history (e.g., IBD, immunosuppression or hemodialysis)
- Plan of Care
  - Contact precautions if diarrhea is present
  - Stool assay
  - Initiation of antibiotics if indicated

### Numerator Options:

- Performance Met: Patients who did have a C. difficile infection risk assessment, AND if high-risk, a plan of care for C. difficile documented on the day of or day after hospital

admission

- Medical Performance Exclusion (Denominator Exception): Patients who did not have a C. difficile infection risk assessment, AND if high risk, a plan of care for C. difficile for medical reasons documented by the Eligible Professional (e.g., C. difficile infection already documented prior to hospital admission, patients unable to provide history, patients on comfort measures)
- Performance Not Met: Patients who did not have a C. difficile infection risk assessment, AND if high risk, a plan of care for C. difficile documented on the day of or day after hospital admission, no reason specified

**Denominator:**

- Any patient  $\geq$  18 years of age evaluated by the Eligible Professional (E/M Codes 99221-99223, 99231- 99233, & 99291-99292 AND Place of Service Indicator: 21)
- Transferred, eloped or AMA patients are excluded

**Denominator Exclusions:** None

**Risk Adjustment:** No

**Rationale:**

*Clostridium difficile* is recognized as one of the most challenging pathogens in hospital and community healthcare settings, with a steadily rising global incidence of infection and concordant increase in mortality. (Tavetin 2013, LoVechio 2012) The Centers for Disease Control and Prevention (CDC) has assigned C. difficile infections (CDI) as an urgent threat because of its association with antibiotic use and high mortality and morbidity. (CDC 2013) Approximately 83,000 of the half a million patients who developed C. difficile in 2011 experienced at least one recurrence, and 29,000 died within 30 days of the initial diagnosis (CDC 2013). Hospitalized CDI patients have a 2.5 times increased 30-day mortality rate compared to in-patients without diarrhea; the CDI-related mortality is approximately 10%. (CDC 2013)

C. difficile infections can be prevented by using infection control recommendations and more careful antibiotic use. Numerous guidelines from the Centers for Disease Control and Prevention (CDC), the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the American Hospital Association (AHA), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Joint Commission recommend risk assessment of hospitalized patients to guide prevention and treatment. (Dubberke 2014, Cohen 2010, Bauer 2009). Multiple risk assessment tools have been developed (Cohen 2010, Tabak 2015, Kuntz 2016, Smith 2014) and different hospitals implement these assessments according to local protocols. Key risk factors identified in these assessment tools include previous CDI, recent contact with a healthcare facility, recent antibiotic use, immune status, and stomach acid reducing medications.

In the United States, the proportion of hospital discharges in which a patient received a discharge diagnosis for CDI more than doubled between 2000 and 2009. (Lucado 2012) Approximately 96% of patients with symptomatic C. difficile infection had received antimicrobials within the 14 days before the onset of diarrhea and that all had received an antimicrobial within the previous 3 months. (Olson 1994) There is an increased risk of CDI that can persist for many weeks after cessation of antimicrobial therapy and which results from prolonged perturbation of the normal intestinal flora. (Anand 1994) Evidence also suggests that

CDI resulting from exposure to *C. difficile* in a healthcare facility can have onset after discharge. (Palmore 2005, Chang 2006, Mayfield 2006). Advanced age is also an important risk factor for CDI, as evidenced by the several fold higher age-adjusted rate of CDI among persons more than 64 years of age. (McDonald 2006, Pepin 2004). Immunosuppression (chemotherapy, HIV, etc) is another risk factor for CDI. (Bilgrami 1999, Gorshulter 2001, Sanchez 2005) Epidemiologic associations with CDI have also been found for acid-suppressing medications such as histamine-2 blockers (HR2A) and proton pump inhibitors (PPI). (Dial 2005, Cunningham 2003, Dial 2004).

The CDC, IDSA, and SHEA currently recommend placing patients with diarrhea under contact precautions while *C. difficile* testing is pending. To decrease transmission, it is essential to place symptomatic patients under contact precautions as soon as diarrhea symptoms are recognized, as this is the period of greatest *C. difficile* shedding and Contamination (Sethi 2010, Dubberke 2014) Contact precautions should remain in place for the duration of CDI illness when caring for patients with CDI, and some experts recommend continuing contact precautions for at least 48 hours after diarrhea resolves. (Sethi 2010). Assuring that patients with CDI are receiving appropriate severity-based treatment for their infection should be an additional goal for antimicrobial stewardship programs and may improve clinical outcome of CDI in these patients. (Dubberke 2014).

Despite recent CDI infection and control efforts, CDI remains at historically high rates. (Dubberke 2014) The CDC's 2015 Annual Report for the Emerging Infections Program for *Clostridium difficile* Infection reported the incidence of healthcare associated CDI to be 82 per 100,000, community acquired to be 65 per 100,000, and the overall incidence rate to be 148 per 100,000. (CDC 2015) Multiple states have reported increased rates of *C. difficile* infection and mortality, noting more severe disease that is more virulent, and more resistant to traditional antibiotics for treatment. (CDC 2017 Fact Sheet)

### **Selected References:**

- Anand A, Bashey B, Mir T, et al. Epidemiology, clinical manifestations, and outcome of *Clostridium difficile*–associated diarrhea. *Am J Gastroenterol* 1994;89:519–523.
- Bauer MP, Kuijper EJ, van Dissel JT; European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for *Clostridium difficile* infection (CDI). *Clin Microbiol Infect*. 2009 Dec;15(12):1067-79.
- Bilgrami S, Feingold JM, Dorsky D, et al. Incidence and outcome of *Clostridium difficile* infection following autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant* 1999;23:1039–1042.
- Centers for Disease Control and Prevention. 2015 Annual Report for the Emerging Infections Program for *Clostridium difficile* Infection. 2015. <https://www.cdc.gov/hai/eip/pdf/cdiff/2015-CDI-Report.pdf>
- Centers for Disease Control and Prevention. *Clostridium difficile* Infections Across the U.S. Fact Sheet. Last accessed Oct 2017. <https://www.cdc.gov/hai/eip/pdf/cdiff-factsheet.pdf>
- Centers for Disease Control & Prevention. Antibiotic Resistance Threats in the United States, 2013. U.S. Department of Health and Human Services.2013. <http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf>
- Centers for Disease Control and Prevention. Frequently asked questions about *Clostridium difficile* for healthcare providers. Centers for Disease Control and Prevention website. 2005. [http://www.cdc.gov/HAI/organisms/cdiff/Cdiff\\_faqs\\_HCP.html](http://www.cdc.gov/HAI/organisms/cdiff/Cdiff_faqs_HCP.html).
- Chang H, Parada J, Evans C, et al. Onset of symptoms and time to diagnosis of *Clostridium*

*difficile* diarrhea among outpatients discharged from an acute care hospital [abstract]. In: Proceedings of The 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America; March 18–21, 2006; Chicago, IL: 108–109.

- Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). *Infect Control Hosp Epidemiol*. 2010 May;31(5):431-55. doi: 10.1086/651706.
- Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for *clostridium difficile* diarrhoea. *J Hosp Infect* 2003;54:243–245.
- Dial S, Alrasadi K, Manoukian C, et al. Risk of *Clostridium difficile* diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. *CMAJ* 2004;171:33–38.
- Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired *Clostridium difficile*–associated disease. *JAMA* 2005;294:2989–2995.
- Dubberke ER, Carling P, Carrico R, Donskey CJ, Loo VG, McDonald LC, Maragakis LL, Sandora TJ, Weber DJ, Yokoe DS, Gerding DN. Strategies to prevent *Clostridium difficile* infections in acute care hospitals: 2014 update. *Infect Control Hosp Epidemiol*. 2014 Sep;35 Suppl 2:S48-65
- Gorschluter M, Glasmacher A, Hahn C, et al. *Clostridium difficile* infection in patients with neutropenia. *Clin Infect Dis* 2001;33:786–791.
- Kuntz JL, Smith DH, Petrik AF, Yang X, Thorp ML, Barton T, Barton K, Labreche M, Spindel SJ, Johnson ES. Predicting the Risk of *Clostridium difficile* Infection upon Admission: A Score to Identify Patients for Antimicrobial Stewardship Efforts. *Perm J*. 2016 Winter;20(1):20-5.
- Lo Vecchio A, Zacur GM. *Clostridium difficile* infection: an update on epidemiology, risk factors, and therapeutic options. *Curr Opin Gastroenterol*. 2012;28:1–9.
- Lucado J, Gould C, Elixhauser A. *Clostridium difficile* Infection (CDI) Hospital Stays, 2009. HCUP Statistical Brief 124. Rockville, MD: Agency for Healthcare Research and Quality, 2012. <http://www.hcup-us.ahrq.gov/reports/statbriefs/sbl24.pdf>
- Mayfield J, McMullen K, Dubberke E. Comparison of *Clostridium difficile*–associated disease rates using a traditional vs. expanded definition. In: Proceedings of The 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America; March 18–21, 2006; Chicago, IL: 115.
- McDonald LC, Owings M, Jernigan DB. *Clostridium difficile* infection in patients discharged from US short-stay hospitals, 1996–2003. *Emerg Infect Dis* 2006;12:409–415.
- Olson MM, Shanholtzer CJ, Lee JT Jr, et al. Ten years of prospective *Clostridium difficile*–associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982–1991. *Infect Control Hosp Epidemiol* 1994;15:371–381.
- Palmore TN, Sohn S, Malak SF, et al. Risk factors for acquisition of *Clostridium difficile*–associated diarrhea among outpatients at a cancer hospital. *Infect Control Hosp Epidemiol* 2005;26:680–684.
- Pepin J, Valiquette L, Alary ME, et al. *Clostridium difficile*–associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. *CMAJ* 2004;171:466-472.
- Samore MH, DeGirolami PC, Tlucko A, et al. *Clostridium difficile* colonization and diarrhea at a tertiary care hospital. *Clin Infect Dis* 1994;18: 181–187.
- Sanchez TH, Brooks JT, Sullivan PS, et al. Bacterial diarrhea in persons with HIV infection,

United States, 1992–2002. Clin Infect Dis 2005;41:1621–1627.

- Sethi AK, Al Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of *Clostridium difficile* during and after treatment of *C. difficile* infection. Infect Control Hosp Epidemiol 2010;31(1):21-27.
- Smith LA, Chan CK, Halm M, Slattery W, Lindquist R, Savik K. Development and validation of a *Clostridium difficile* risk assessment tool. AACN Adv Crit Care. 2014 Oct-Dec;25(4):334-46.
- Tabak YP, Johannes RS, Sun X, Nunez CM, McDonald LC. Predicting the risk for hospital-onset *Clostridium difficile* infection (HO-CDI) at the time of inpatient admission: HO-CDI risk score. Infect Control Hosp Epidemiol. 2015 Jun;36(6):695-701. Epub 2015 Mar 10.
- Tattevin P, Buffet-Bataillon S, Donnio PY, Revest M, Michelet C. *Clostridium difficile* infections: do we know the real dimensions of the problem? Int J Antimicrob Agents. 2013;42:S36–40.



## **H-CPR (Hospitalist – Clinical Performance Registry) Measure #22**

**Measure Title:** Critical Care Transfer of Care – Use of Verbal Checklist or Protocol

**Inverse Measure:** No

**Measure Description:** Percentage of Adult Patients Transferred from the Critical Care Service to a Non-critical Care Service Who Had Documented Use of a Verbal Protocol for the Transfer of Care Between the Transferring Clinician and the Accepting Clinician

**National Quality Strategy Domain:** Communication and Care Coordination

**Care Setting:** Inpatient/Hospital

**Telehealth?:** Yes

**Type of Measure:** Process, High Priority

**Meaningful Measure Area:** Transfer of Health Information and Interoperability

**Current Clinical Guideline:** The Joint Commission and AHRQ have identified improved patient hand-offs as a national patient safety goal

**Clinical Category:** Care Coordination

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Numerator:** Patients transferred from the critical care service to a non-critical care service for whom a verbal (in person or telephonic) checklist or protocol which includes the key transfer of care elements was utilized

### Definitions:

- Transfer of Care Checklist or Protocol – The key transfer of care elements include:
  - Review of the overall ICU hospital course
  - Results of pertinent labs and imaging studies
  - Pending studies such as imaging and labs not yet resulted for follow-up by the accepting clinician

### Numerator Options:

- Performance Met: Patients who did have utilization of a verbal (in person or telephonic) checklist or protocol documented
- Performance Not Met: Patients who did not have utilization of a verbal (in person or telephonic) checklist or protocol documented

### **Denominator:**

- Any patient ≥ 18 years of age evaluated by the Eligible Professional (E/M Codes 99221-99223, 99231- 99233, & 99291- 99292 AND Place of Service Indicator: 21) PLUS
- Patients transferred from critical care service to non-critical care service

- Patients discharged from the hospital directly from critical care service are excluded
- Transferred, eloped or AMA patients are excluded

**Denominator Exclusions:** None

**Risk Adjustment:** No

**Rationale:**

Hospital handoffs are believed to be a key locus of communication breakdown that can endanger patient safety and undermine quality of care. (Cohen 2012) The Joint Commission has identified improving hand-offs as a national patient safety goal, citing problems with communication as a frequent cause of medical errors. (TJC 2007) Similarly, the Agency on Healthcare Research and Quality (AHRQ) has identified improving handoffs in care as a priority in nationwide efforts to improve patient safety. (AHRQ 2016). Transfers from intensive care units to acute care units represent a complex care transition for hospitalized patients. (Halvorson 2016)

The Society for Critical Care Medicine recommends that a standardized process for discharge from the Intensive Care Unit (ICU) be used and that both oral and written formats for the report may reduce readmission rates. (Nates 2016) At an urban teaching hospital, institution of a discharge process that included a transfer phone call, charted care summary, and discharge physical re-examination by the discharging provider resulted in a decrease in readmission rate from 41% to 10%. Of those readmitted cases, 30% were found to be noncompliant with the new processes. (Frankel 2006) In another study, the institution of ICU discharge phone reports by the ICU physician or nurse practitioner, nurse, and respiratory therapist also resulted in a significant decrease in readmissions. (Hess 2010)

Several tools for patient hand-off have been studied. (Arora 2005, Bump 2012, Wheat 2012) Effective interventions include improved communication and coordination of care to facilitate timely, complete and accurate handover information. Effective interventions result in improved continuity of care and in reduced adverse events. (van Sluisveld 2015, Cohen 2012) While the primary objective of a handoff is to provide accurate information to the accepting clinician about a patient’s care, treatment, current condition and any recent or anticipated changes, a standardized approach to hand-off communications that includes an opportunity to ask and respond to questions is valuable. (Arora 2006, TJC 2007)

There is mounting evidence that communication and hand-off failures are a root cause of two-thirds of sentinel events in hospitals. (Fryman 2017)

**Selected References:**

- Arora V, Johnson J, Lovinger D, Humphrey HJ, Meltzer DO. Communication failures in patient sign-out and suggestions for improvement: a critical incident analysis. *Qual Saf Health Care.*2005;14:401–7.
- Bump GM, Jacob J, Abisse SS, Bost JE, Elnicki DM. Implementing faculty evaluation of written sign-out. *Teach Learn Med.* 2012;24:231–7.
- Wheat D, Co C, Manochakian R, Rich E. An assessment of patient sign-outs conducted by University at Buffalo internal medicine residents. *Am J Med Qual.* 2012;27:39–47.
- Nates JL1, Nunnally M, Kleinpell R, Blosser S, Goldner J, Birriel B, Fowler CS, Byrum D, Miles WS, Bailey H, Sprung CL. ICU Admission, Discharge, and Triage Guidelines: [A](#)

[Framework to Enhance Clinical Operations, Development of Institutional Policies, and Further Research](#). Crit Care Med. 2016 Aug;44(8):1553-602. doi: 10.1097/CCM.0000000000001856.

- Fryman C, Hamo C, Raghavan S, Goolsarran N. A Quality Improvement Approach to Standardization and Sustainability of the Hand-off Process. BMJ Qual Improv Rep. 2017 Apr 6;6(1). pii: u222156.w8291. doi: 10.1136/bmjquality.u222156.w8291. eCollection 2017.
- Joint Commission on Accreditation of Healthcare Organizations: 2007 National Patient Safety Goals Hospital Version Manual Chapter. 2007  
[http://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/07\\_hap\\_cah\\_npsgs.htm](http://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/07_hap_cah_npsgs.htm)
- Agency for Healthcare Research and Quality (AHRQ). Handoffs and Signouts 2016 [updated July 2016]. Available from: <https://psnet.ahrq.gov/primers/primer/9/handoffs-and-signouts>.
- Frankel HL, Foley A, Norway C, et al: Amelioration of increased intensive care unit service readmission rate after implementation of work-hour restrictions. J Trauma 2006; 61:116–121
- Hess DR, Tokarczyk A, O'Malley M, et al: The value of adding a verbal report to written handoffs on early readmission following prolonged respiratory failure. Chest 2010; 138:1475–1479
- van Sluisveld N, Hesselink G, van der Hoeven JG, Westert G, Wollersheim H, Zegers M. Improving clinical handover between intensive care unit and general ward professionals at intensive care unit discharge. Intensive Care Med. 2015 Apr;41(4):589-604. doi: 10.1007/s00134-015-3666-8. Epub 2015 Feb 12. Review.
- Halvorson S, Wheeler B, Willis M, Watters J, Eastman J, O'Donnell R, Merkel M. A multidisciplinary initiative to standardize intensive care to acute care transitions. Int J Qual Health Care. 2016 Oct;28(5):615-625. Epub 2016 Aug  
<https://www.ncbi.nlm.nih.gov/pubmed/27535085>
- Ong MS, Coiera E. A Systematic Review of Failures in Handoff Communication During Intrahospital Transfers. Jt Comm J Qual Patient Saf. 2011 Jun;37(6):274-84.  
[http://www.jointcommissionjournal.com/article/S1553-7250\(11\)37035-3/pdf](http://www.jointcommissionjournal.com/article/S1553-7250(11)37035-3/pdf)
- Gupta K, Mueller SK. Interhospital transfers: The need for standards. J Hosp Med. 2015 Jun;10(6):415-7. doi: 10.1002/jhm.2320. Epub 2015 Jan 28.  
<https://www.ncbi.nlm.nih.gov/pubmed/25627794>
- McMullan A, Parush A, Momtahan K. Transferring patient care: patterns of synchronous bidisciplinary communication between physicians and nurses during handoffs in a critical care unit. J Perianesth Nurs. 2015 Apr;30(2):92-104. doi: 10.1016/j.jopan.2014.05.009. Epub 2014 Oct 30. <https://www.ncbi.nlm.nih.gov/pubmed/25813295>
- Abraham J, Kannampallil TG, Almoosa KF, Patel B, Patel VL. Comparative evaluation of the content and structure of communication using two handoff tools: implications for patient safety. J Crit Care. 2014 Apr;29(2):311.e1-7. doi: 10.1016/j.jcrc.2013.11.014. Epub 2013 Nov 23. <https://www.ncbi.nlm.nih.gov/pubmed/24360818>

## **E-CPR (Emergency – Clinical Performance Registry) Measure #51**

**Measure Title:** Discharge Prescription of Naloxone after Opioid Poisoning or Overdose

**Inverse Measure:** No

**Measure Description:** Percentage of Opioid Poisoning or Overdose Patients Presenting to An Acute Care Facility Who Were Prescribed Naloxone at Discharge

**National Quality Strategy Domain:** Effective Clinical Care

**Care Setting:** Multiple Care Settings - Emergency Department and Services, Inpatient/Hospital, Urgent Care, Primary Care

**Telehealth?:** Yes

**Type of Measure:** Process, High Priority

**Meaningful Measure Area:** Prevention and Treatment of Opioid and Substance Use Disorders

**Current Clinical Guideline:** Numerous organizations, including the American Medical Association and American Society of Addiction Medicine, recommend increased access to Naloxone for patients who are at high risk to reverse the effects and reduce the chance of death in the event of an opioid overdose, which includes expanded prescribing practices by clinicians

**Clinical Category:** Opioids

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Numerator:** Patients Who Were Prescribed Naloxone AND Educated About Utilization at Discharge

- Performance Met: Naloxone was prescribed at discharge AND patient was educated about use
- Medical Performance Exclusion (Denominator Exception): Naloxone was not prescribed at discharge due to medical reasons such as allergy
- Performance Not Met: Naloxone medication was not prescribed at discharge OR patient was not educated about use

**Numerator Exclusions:** None

**Denominator:**

- Any patient evaluated by the Eligible Professional (E/M Codes 99217, 99234-99236, 99238-99239, 99281-99285, 99291-99292) PLUS
- Diagnosis of opioid poisoning from heroin, methadone, morphine, opium, codeine, hydrocodone, or another opioid substance
  - ICD-10: T40.0X1A, T40.0X1D, T40.0X1S, T40.0X2A, T40.0X2D, T40.0X2S, T40.0X3A, T40.0X3D, T40.0X3S, T40.0X4A, T40.0X4D, T40.0X4S, T40.1X1A,

T40.1X1D, T40.1X1S, T40.1X2A, T40.1X2D, T40.1X2S, T40.1X3A, T40.1X3D, T40.1X3S, T40.1X4A, T40.1X4D, T40.1X4S, T40.2X1A, T40.2X1D, T40.2X1S, T40.2X2A, T40.2X2D, T40.2X2S, T40.2X3A, T40.2X3D, T40.2X3S, T40.2X4A, T40.2X4D, T40.2X4S, T40.3X1A, T40.3X1D, T40.3X1S, T40.3X2A, T40.3X2D, T40.3X2S, T40.3X3A, T40.3X3D, T40.3X3S, T40.3X4A, T40.3X4D, T40.3X4S, T40.411A, T40.411D, T40.411S, T40.412A, T40.412D, T40.412S, T40.413A, T40.413D, T40.413S, T40.414A, T40.414D, T40.414S, T40.421A, T40.421D, T40.421S, T40.422A, T40.422D, T40.422S, T40.423A, T40.423D, T40.423S, T40.424A, T40.424D, T40.424S, T40.491A, T40.491D, T40.491S, T40.492A, T40.492D, T40.492S, T40.493A, T40.493D, T40.493S, T40.494A, T40.494D, T40.494S, T40.601A, T40.601D, T40.601S, T40.602A, T40.602D, T40.602S, T40.603A, T40.603D, T40.603S, T40.604A, T40.604D, T40.604S, T40.691A, T40.691D, T40.691S, T40.692A, T40.692D, T40.692S, T40.693A, T40.693D, T40.693S, T40.694A, T40.694D, T40.694S

○

- Transferred, eloped or AMA patients are excluded

**Denominator Exclusions:** None

**Risk Adjustment:** No

**Rationale:**

The opioid epidemic in the United States claims hundreds of lives every day. One of medicine's best tools against this epidemic is Naloxone. Naloxone has proven to be the most effective method for reversing an opioid overdose in patients of all characteristics and has been shown to greatly reduce the chance of fatality. Naloxone is a non-selective, short-acting opioid receptor antagonist used to treat opioid induced respiratory depression. It is safe, has no addictive potential, and has mild side effects. The use of naloxone has been consistently recommended and promoted by numerous health organizations including the American Medical Association. Increasing the availability of Naloxone among the public, law enforcement, and community organizations is advocated by many organizations including the American Society of Addiction Medicine and is a priority of numerous states and federal health agencies. Despite these recommendations, a survey of opioid-related policies in New England emergency departments found that only 12% of departments would prescribe naloxone for patients at risk of opioid overdose after discharge. Promoting the prescription of Naloxone for patients discharged after an opioid overdose will ensure that the chance of fatality across all patient populations is significantly reduced.

**Selected References:**

- Bird, S. M., McAuley, A., Perry, S., & Hunter, C. (2016). Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths: a before (2006–10) versus after (2011–13) comparison. *Addiction*, 111(5), 883-891.
- CMS finalizes measures to help combat opioid crisis. (2018, April 16). Retrieved from <https://www.the-hospitalist.org/hospitalist/article/162747/pain/cms-finalizes-measures-help-combat-opioid-crisis/page/0/3>
- Dorp, E. L., Yassen, A., & Dahan, A. (2007). Naloxone treatment in opioid addiction: The risks and benefits. *Expert Opinion on Drug Safety*, 6(2), 125-132. doi:10.1517/14740338.6.2.125

- Dunne, R. B. (2018). Prescribing naloxone for opioid overdose intervention. *Pain Management*, 8(3).
- Dwyer, K., Walley, A. Y., Langlois, B. K., Mitchell, P. M., Nelson, K. P., Cromwell, J., & Bernstein, E. (2015). Opioid education and nasal naloxone rescue kits in the emergency department. *Western Journal of Emergency Medicine*, 16(3), 381.
- Help save lives: Co-prescribe naloxone to patients at risk of overdose. (2017). AMA Opioid Task Force. Retrieved from <https://www.end-opioid-epidemic.org/wp-content/uploads/2017/08/AMA-Opioid-Task-Force-naloxone-one-pager-updated-August-2017-FINAL-1.pdf>
- Kestler, A., Buxton, J., Meckling, G., Giesler, A., Lee, M., Fuller, K., Scheuermeyer, F. (2017). Factors associated with participation in an emergency department–based take-home naloxone program for at-risk opioid users. *Annals of emergency medicine*, 69(3), 340-346.
- Kmeic, J., DO. (n.d.). Module 4: Special Aspects of the Treatment of Substance Use Disorders. Retrieved June 13, 2018, from <http://pcssnow.org/wp-content/uploads/2016/08/Prescribing-Naloxone-to-Patients-for-Overdose-Reversal.pdf>
- Kounang, N. (2017, October 30). Naloxone reverses 93% of overdoses. Retrieved from <https://www.cnn.com/2017/10/30/health/naloxone-reversal-success-study/index.html>
- Public Policy Statement on the Use of Naloxone for the Prevention of Opioid Overdose Deaths. (n.d.). Retrieved June 13, 2018, from <https://www.asam.org/docs/default-source/public-policy-statements/use-of-naloxone-for-the-prevention-of-opioid-overdose-deaths-final.pdf?sfvrsn=4> American Society of Addiction Medicine
- Reardon, J. M., Harmon, K. J., Schult, G. C., Staton, C. A., & Waller, A. E. (2016). Use of diagnosis codes for detection of clinically significant opioid poisoning in the emergency department: A retrospective analysis of a surveillance case definition. *BMC emergency medicine*, 16(1), 11.
- Wong, F., Edwards, C. J., Jarrell, D. H., & Patanwala, A. E. (2018). Comparison of lower-dose versus higher-dose intravenous naloxone on time to recurrence of opioid toxicity in the emergency department. *Clinical Toxicology*, 1-6.

## **H-CPR (Hospitalist – Clinical Performance Registry) Measure #23**

**Measure Title:** Avoidance of Echocardiogram and Carotid Ultrasound for Syncope

**Inverse Measure:** No

**Measure Description:** Percentage of Patients Presenting with Syncope Who Did Not Have an Echocardiogram or Carotid Ultrasound Ordered

**National Quality Strategy Domain:** Efficiency and Cost Reduction

**Care Setting:** Inpatient/Hospital

**Telehealth?:** Yes

**Type of Measure:** Process, High Priority

**Meaningful Measure Area:** Appropriate Use of Healthcare

**Current Clinical Guideline:** American College of Cardiology, American Heart Association, European Society of Cardiology

**Clinical Category:** Syncope

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Numerator:** Patients That Did NOT Have an Echocardiogram or Carotid Ultrasound Ordered.

- Performance Met: Echocardiogram AND Carotid Ultrasound NOT ordered
- Medical Performance Exclusion (Denominator Exception): Cardiac Etiology of Syncope Suspected or Determined (i.e. abnormal cardiac exam (new murmur, bruit), abnormal EKG, cardiac dysrhythmia, abnormal cardiac biomarkers, chest pain, shortness of breath, known heart disease, known or suspected structural heart disease); Neurologic Etiology of Syncope Suspected or Determined (i.e. abnormal neurologic exam, focal neurologic deficit).
- Performance Not Met: Echocardiogram and/or Carotid ultrasound Ordered

**Numerator Exclusions:** None

**Denominator:**

- Any patient  $\geq$  18 years of age evaluated by the Eligible Professional PLUS
- Admitted or Placed in Observation Status PLUS
- Diagnosis of Syncope
  - ICD-10: R55
- Transferred, eloped, AMA or expired patients are excluded

**Denominator Exclusions:** None

## **Risk Adjustment: No**

### **Rationale:**

Syncope, defined as a transient loss of consciousness with rapid spontaneous recovery, is a common condition for which patients seek medical attention. It accounts for up to 6% of all hospital admissions. Given the broad range of causes (neurologic, vascular, metabolic, cardiac, psychological, etc.) for syncope, clinicians may pursue many different diagnostic tests as part of their evaluation. Several studies have shown that many of these tests, including routine use of echocardiography and carotid ultrasonography, can be unnecessary and unlikely to contribute to the etiologic diagnosis and management of syncope. In a study of 2106 patients who received a battery of diagnostic testing during admission following a syncope episode, only 2% of echocardiograms performed revealed findings that contributed to the syncopal episode. An even smaller percentage of performed carotid ultrasounds affected the diagnosis or helped to determine the etiology of syncope. (Mendu) Another retrospective review of 128 patients admitted for syncope found that “for patients without suspected cardiac disease after history, physical examination, and electrocardiography, the echocardiogram did not appear to provide additional useful information.” (Recchia) Another study of 1038 patient records coded as “syncope” revealed that only 0.94% of performed echocardiograms and 0% of performed carotid ultrasounds helped to establish the cause of syncope. (Johnson)

Per the 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients with Syncope, “routine cardiac imaging [transthoracic echocardiography] is not useful in the evaluation of patients with syncope unless cardiac etiology is suspected on the basis of an initial evaluation, including history, physical examination, or ECG.” Also, carotid artery imaging is not recommended in the routine evaluation of patients with syncope in the absence of focal neurological findings that support further evaluation. “The evidence suggests that routine neurologic testing [including carotid ultrasound] is of very limited value in the context of syncope evaluation and management; the diagnostic yield is low, with very high cost per diagnosis.” (Shen)

According to the 2018 European Society of Cardiology (ESC) Guidelines for the Diagnosis and Management of Syncope, echocardiogram is only indicated if there is previous known heart disease or data suggestive of structural heart disease or syncope secondary to cardiovascular cause. (Brignole)

### **Selected References:**

Brignole M, Moya A, de Lange FJ, et al. 2018 ESC Guidelines for the Diagnosis and Management of Syncope. *European Heart Journal*. 39(21) 01 Jun 2018; 1883-1948.

Johnson PC, Ammar H, Zohdy W, et al. Yield of diagnostic tests in evaluating syncope presenting to a community hospital. *South Med J*. 2014; 107: 707-14.

Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients with Syncope: A Report of the American College of



Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation*. 2017; 136: e60-e122.

Mendu ML, McAvay G, Lampert R, et al. Yield of diagnostic tests in evaluating syncopal episodes in older patients. *Arch Intern Med*. 2009;169:1299–305.

Recchia D, Barzilai B. Echocardiography in the evaluation of patients with syncope. *J Gen Intern Med*. 1995;10:649–55

## **E-CPR (Emergency – Clinical Performance Registry) Measure #56**

**Measure Title:** Opioid Withdrawal: Initiation of Medication-Assisted Treatment (MAT) and Referral to Outpatient Opioid Treatment

**Inverse Measure:** No

**Measure Description:** Percentage of Patients Presenting with Opioid Withdrawal Who Were Given Medication-Assisted Treatment and Referred to Outpatient Opioid Treatment

**National Quality Strategy Domain:** Patient Safety

**Care Setting:** Multiple Care Settings – All Settings

**Telehealth?:** Yes

**Type of Measure:** Process, High Priority

**Meaningful Measure Area:** Prevention and Treatment of Opioid and Substance Use Disorders

**Current Clinical Guideline:**

**Clinical Category:** Opioids

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Numerator:** Patients Who Were Given Medication-Assisted Treatment (MAT) and, at Time of Discharge to Home or Home Health, Referred to Outpatient Opioid Treatment

- Performance Met: Buprenorphine or Methadone ordered AND, at time of discharge to home or home health, outpatient opioid treatment referral made
- Medical Performance Exclusion (Denominator Exception): Refusal of care, allergy to medicine, altered mental status, Buprenorphine or Methadone not clinically indicated
- Performance Not Met: Buprenorphine or Methadone not ordered OR Buprenorphine or Methadone ordered BUT outpatient opioid treatment referral not made at time of discharge to home or home health

**Numerator Exclusions:** None

**Denominator:**

- Any patient  $\geq 18$  years of age evaluated by the Eligible Professional (E/M Codes 99217, 99234-99236, 99238-99239, 99281-99285, 99291-99292, 99201-99205, 99212-99215) PLUS
- Diagnosis of opioid abuse or dependence with withdrawal
  - ICD-10: F11.13, F11.23
- Transferred, eloped, AMA or expired patients are excluded

**Denominator Exclusions:** None

## **Risk Adjustment: No**

### **Rationale:**

According to the 2019 National Survey on Drug Use and Health, 2 million people in the United States had an opioid use disorder in 2018. In 2018, 47,600 people died from overdosing on opioids – that means that more than 130 deaths occurred every day from opioid-related drug overdoses.

Patients with opioid use disorder represent a vulnerable population that often seeks care in Emergency Departments and acute care hospitals. Often, they seek care due to withdrawal symptoms which may include abdominal cramping, nausea, vomiting, diarrhea, anxiety, restlessness, tremor, and muscle aches. Without appropriate treatment, these individuals may seek continued use of prescription opioids and/or illegal opioids such as heroin to transiently alleviate their symptoms. Medication Assisted Treatment (MAT) with opioid agonist treatment including Buprenorphine and Methadone has been shown to be effective in treating these individuals. These medications decrease withdrawal, craving, and opioid use.

A randomized clinical trial performed involving 329 opioid-dependent patients from 2009-2013 demonstrated superiority of buprenorphine treatment compared to brief intervention and referral. Treatment led to increased engagement in addiction treatment, reduced self-reported illicit opioid use, and decreased use of inpatient addiction treatment services.

### **Selected References:**

1. [Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.](#)
2. [Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.](#)
3. [A Quality Framework for Emergency Department Treatment of Opioid Use Disorder.](#)
  - a. This is a good review that includes recommendations for opioid-related quality measures (including an MAT measure)
4. [Emergency Departments — A 24/7/365 Option for Combating the Opioid Crisis](#)
5. [https://www.hhs.gov/opioids/sites/default/files/2019-11/Opioids%20Infographic\\_letterSizePDF\\_10-02-19.pdf](https://www.hhs.gov/opioids/sites/default/files/2019-11/Opioids%20Infographic_letterSizePDF_10-02-19.pdf)